Innovio's Voceryq Receives FDA Accelerated Approval

Innovio has received FDA accelerated approval for its drug Voceryq, which aims to reduce the frequency of surgery for recurrent respiratory papillomatosis in adult patients. Innovio is pleased to announce that it has received FDA accelerated approval for its drug Voceryq. The medication is intended for treating recurrent respiratory papillomatosis (RRP) in adult patients, specifically with the aim of reducing the frequency of surgical intervention.